Sign in
CompletedNo phase

Rapid Molecular Diagnosis of Sepsis in the Intensive Care Unit

Key facts

Who runs it
Maastricht University Medical Center
Where
Netherlands1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
300 people enrolled
Started
1 May 2024
Ended
18 Dec 2025
Type of study
Observational
Record updated
13 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • -Patients are included when routine blood cultures are ordered for diagnosis of bloodstream infections

Who cannot take part

  • -N/A

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Rapid diagnosis of sepsis is crucial for treatment and survival. Currently, blood culture takes 48 hours-5 days to complete. After starting antimicrobial treatment blood culture results are not reliable. As a result, empirical broad spectrum antimicrobial therapy is mostly used. This implies possible antimicrobial over- or under treatment which is associated with increased antimicrobial resistance development. Early identification of the causative pathogen of sepsis will therefore have a major impact on the adequate treatment and reduction of high mortality rates. To date, there is not a single molecular diagnostic test available on the market to detect all putative causative bacterial pathogens of sepsis. In this study, the investigators will develop and validate a completely new molecular sepsis approach based on pathogen DNA detection, as an alternative to culture.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Rapid Molecular Detection of Sepsis in Whole Blood
Record updated
13 October 2026